| Abstract | Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients develop treatment-resistant tumors. In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide. |
| Authors | Lisa M Neff, Michelle Weil, Alan Cole, Thomas R Hedges, William Shucart, Donald Lawrence, Jay-Jiguang Zhu, Arthur S Tischler, Ronald M Lechan
(Affiliation: Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Tufts-New England Medical Center, Boston, MA 02111, USA.)
|
| Journal | Pituitary
(Pituitary)
Vol. 10
Issue 1
Pg. 81-6
( 2007)
ISSN: 1386-341X United States |
| PMID | 17285366
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Dopamine Agonists
- Dacarbazine
- temozolomide
- Prolactin
|
| Topics |
- Dacarbazine
(adverse effects, analogs & derivatives, therapeutic use)
- Dopamine Agonists
(therapeutic use)
- Drug Resistance, Neoplasm
- Female
- Humans
- Middle Aged
- Pituitary Neoplasms
(diagnosis, drug therapy)
- Prolactin
(blood)
- Prolactinoma
(diagnosis, drug therapy)
|
